Showing results (101-110 of 165) with videos related to

Sort By:
Pageof 17
Annals of Hematology|March 6, 2014
Limited clinical benefit for surveillance PET-CT scanning in patients with histologically transformed lymphoma in complete metabolic remission following primary therapyChan Y Cheah, Michael Dickinson, Michael S Hofman, et al.
British Journal of Cancer|June 29, 2013
Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapyC Y Cheah, M S Hofman, M Dickinson, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 5, 2023
High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell LymphomaKatharine L Lewis, Lasse H Jakobsen, Diego Villa, et al.
Leukemia & Lymphoma|April 15, 2014
The utility and limitations of (18)F-fluorodeoxyglucose positron emission tomography with computed tomography in patients with primary mediastinal B-cell lymphoma: single institution experience and literature reviewChan Y Cheah, Michael S Hofman, John F Seymour, et al.
Future Oncology (London, England)|November 15, 2022
BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphomaToby A Eyre, Nirav N Shah, Martin Dreyling, et al.
British Journal of Haematology|December 10, 2015
Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer CenterDai Chihara, Chan Y Cheah, Jason R Westin, et al.
British Journal of Haematology|May 6, 2025
An international real-world study of primary vitreoretinal lymphoma from the Australasian lymphoma alliance and collaboratorsCatherine Tang, Catriona Downie, Mandeep S Sagoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 26, 2013
Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma NetworkC Y Cheah, A George, E Giné, et al.
Blood|October 26, 2023
CAR T cells and time-limited ibrutinib as treatment for relapsed/refractory mantle cell lymphoma: the phase 2 TARMAC studyAdrian Minson, Nada Hamad, Chan Y Cheah, et al.
Blood Advances|February 5, 2026
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory Richter's transformationKatharine Louise Lewis, Sarit E Assouline, Ross Ian Baker, et al.
Pageof 17